Raav2/5-Hnaglu
Hemophilia A
University College, Londongene_therapyPhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 73/ 100
Competitive context
66 Active assets in the Hemophilia A cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Turoctocog Alfa Novo Nordisk A/S | Phase 4 | A |
Eptacog Alfa AryoGen Pharmed Co. | Phase 4 | A |
Rurioctocog Alfa Pegol Takeda | Phase 4 | BBB |
Turoctocog Alfa Pegol Novo Nordisk A/S | Phase 3 | BBB |
bay94-9027 Bayer | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Raav2/5-Hnaglu is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →